

Considerations for Potential Future Therapeutic Use of Psychedelic Drugs

Part 15 Hearing | September 14, 2026

U.S. Food and Drug Administration
White Oak Campus
Building 31, Room 1503 - Great Room
10903 New Hampshire Avenue
Silver Spring, MD 20993

FDA LISTENING PANEL

Moderator: Dayle Cristinzio, Director

Office of External Affairs, Public Engagement Staff

Marta Sokolowska, Ph.D., Deputy Center Director for Substance Use and Behavioral Health

Center for Drug Evaluation and Research, Office of the Center Director

Tiffany R. Farchione, M.D., Director, Division of Psychiatry

Center for Drug Evaluation and Research, Office of New Drugs

Bernard Fischer, M.D., Deputy Director, Office of Neuroscience

Center for Drug Evaluation and Research, Office of New Drugs

FEDERAL PARTNER LISTENING PANEL

Daniel Stimson, J.D., Ph.D., Research Analyst

National Institute on Drug Abuse, National Institutes of Health

Neeraj (Jim) Gandotra, M.D., Chief Medical Officer

Substance Abuse and Mental Health Services Administration

Rick Lambert, M.D., Senior Advisor

Substance Abuse and Mental Health Services Administration

Andrew K. Gradison, J.D., Senior Advisor

Veterans Health Administration

Wendy Tenhula, Ph.D., Deputy Chief Research and Development Officer

Office of Research and Development, Veterans Health Administration

Al Bugazia, M.D., Deputy Director, Proactive Health

Advanced Research Projects Agency for Health

AGENDA

11:30 AM – 12:30 PM **Registration**

12:30 – 12:40 PM **Welcome & Overview**

Dayle Cristinzio, Director, Stakeholder Engagement Staff

12:40 – 12:45 PM **Opening Remarks**

Dr. Marta Sokolowska, Deputy Center Director for Substance Use and Behavioral Health, Center for Drug Evaluation and Research

12:45 – 2:45 PM **Public Comments** (2 minutes each)

Provider training and credentialing; Promotion of patient safety
(Questions may be asked by the panel after each speaker concludes)

In-Person Comments

1. **Heidi Allen**, Columbia University
2. **Erin Atkinson**, Prism Wellness
3. **Rajan Dunne**, Sheppard Pratt
4. **Angela Fisher**, Bionic Bloom
5. **Lisa Ginzburg**, Changa Institute
6. **Lynn Marie Morski**, Psychedelic Medicine Association
7. **Valerie Porr**, TARA for Borderline Personality Disorder
8. **Mark Rasenick**, American Brain Coalition
9. **Simeon Schnapper**, JLS
10. **Nikita Tsimmer**, Fountain Health

Virtual Comments

11. **Laura Barrett**, University of Maryland
12. **Geoff Bathje**, Sana Healing Collective
13. **Christine Caldwell**, End of Life Psychedelic Care
14. **Liz Collins**, Liz Collins NMIT
15. **Lida Fatemi**, ABQ Hospice & Palliative Care Co. and UNM School of Medicine
16. **Derek Kozlowski**, *No Affiliation Disclosed*
17. **Lawrence Michael Leeman**, University of New Mexico
18. **Joshua Potocko**, Althea NOLA
19. **Sandy Samberg**, Psychedelic Education Partnership
20. **Michaela Vogt**, NeuroAlchemy

In-Person Comments

21. **Christina Braddock**, Mana Warrior Collective

Considerations for Potential Future Therapeutic Use of Psychedelic Drugs Public Hearing

U.S. Food and Drug Administration

22. **Eileen Brewer**, Eileen's Mission Possible
23. **Dennis Chien**, Pacific Medical Device Consulting LLC
24. **John Eaton**, Wounded Warrior Project
25. **Brigitte Gordon**, Journey Clinical
26. **Gregory Hutchinson**, Emyria Limited
27. **Lakisha Jenkins-Samuels**, Kiona Foundation
28. **Laurel Kilgour**, Psychedelic Bar Association
29. **Heather Kuiper**, Center for Psychedelic Public Health
30. **Jason Roop**, Center for Trait-Based Transformation
31. **Jeremy Rudy**, Sabba Collective

Virtual Comments

32. **Jane Caplan**, East West Global Healing
33. **Pedram Dara**, Psychedelic Lived Experiences
34. **Caroline Dorsen**, U-PEP/NYU Meyers College of Nursing
35. **Peter Hendricks**, University of Alabama at Birmingham and Apollo Pact
36. **Genesee Herzberg**, The International Alliance of Psychedelic Therapy Practitioners
37. **Jawed Kalim**, Compass Pathways
38. **Michael Lawton**, Barrow Neurological Institute
39. **Mark Nicolas**, Neurogenic Consultants Group
40. **Christian Reed**, Mindbloom
41. **Stephanie Seal**, *No Affiliation Disclosed*
42. **Raymond C. Turpin**, The Pearl Institute
43. **Corey Whetzel**, American Pharmacists Association
44. **Shasta Winn**, Myco-Method

2:45 – 2:55 PM

BREAK

2:55 – 4:25 PM

Public Comments (2 minutes each)

Considerations for access; Best practices for data collection and standardization

(Questions may be asked by the panel after each speaker concludes)

In-Person Comments

45. **Tiffany Callis**, The Spirit Nurse Psychedelic Society
46. **Chelsea Cunningham**, *No Affiliation Disclosed*
47. **Jon Dalton**, Nevada Coalition for Psychedelic Medicines
48. **Mary-Elizabeth Gifford**, Clearmind Medicine, Inc.
49. **Odette Hauke**, Odette Alina LLC
50. **Edward Jacobs**, Johns Hopkins
51. **Eric Jansen**, Balanced Veterans Network
52. **Melissa Lavasani**, Psychedelic Medicine Coalition

Considerations for Potential Future Therapeutic Use of Psychedelic Drugs Public Hearing

U.S. Food and Drug Administration

- 53. **Justice Leak**, Therapod LLC
- 54. **Shanetha Lewis**, Maryland Task Force On The Responsible Use of Natural Psychedelics
- 55. **Maksim Tsvetovat**, Research Lambda

Virtual Comments

- 56. **Amber Barnato**, The Dartmouth Institute for Health Policy and Clinical Practice, Geisel School of Medicine
- 57. **Raquel Bennett**, KRIYA Institute
- 58. **Jennifer Bremser**, *No Affiliation Disclosed*
- 59. **Sammy C**, Mindful Health
- 60. **Jagpaul Kaur Deol**, University of British Columbia
- 61. **Rhonda DeSantis**, Psylutions
- 62. **Lawrence Goldkind**, Uniformed Services University of Health Sciences, School of Medicine
- 63. **James Wilson Green**, Rutgers School of Health Professions
- 64. **Sarit Hashkes**, Filament Health
- 65. **James Hosobe**, Arizona Department of Health Services
- 66. **Shraga Israel**, Metanoia
- 67. **Ashley Walsh Kvamme**, Inner State, Inc
- 68. **Kevin Sabet**, Foundation for Drug Policy Solutions
- 69. **Susan Taymor Sagy**, Coalition for Psychedelic Safety and Education
- 70. **Joel Stanley**, Ajna Biosciences
- 71. **Jean C. Vélez Rodríguez**, Puerto Rico Institute for Psychedelic Science, Medicine and Awareness
- 72. **Sean Vina**, UIW
- 73. **Lynn Watkins**, Psychedelics and Pain Association

In-Person Comments

- 74. **Amna Aslam**, Radial
- 75. **Kerthy Hearn**, *No Affiliation Disclosed*
- 76. **Daniel Huson**, Rose City Laboratories LLC
- 77. **Nick Kadysh**, PharmAla Biotech Inc.
- 78. **Richard Mark Langford**, Cy Biopharma
- 79. **Alia Lilienstein**, University of California Berkeley Center for the Science of Psychedelics
- 80. **Jorge Valderrabano**, Agora

4:25 – 4:30 PM

Closing Remarks

Dayle Cristinzio, Director, Public Engagement Staff